- Home
- BARK vs VTYX Comparison
BARK vs VTYX Comparison
Compare BARK & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BARK
- VTYX
- Stock Information
- Founded
- BARK 2011
- VTYX 2018
- Country
- BARK United States
- VTYX United States
- Employees
- BARK N/A
- VTYX N/A
- Industry
- BARK Department/Specialty Retail Stores
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- BARK Consumer Discretionary
- VTYX Health Care
- Exchange
- BARK Nasdaq
- VTYX Nasdaq
- Market Cap
- BARK 146.0M
- VTYX 154.9M
- IPO Year
- BARK N/A
- VTYX 2021
- Fundamental
- Price
- BARK $0.78
- VTYX $3.99
- Analyst Decision
- BARK Strong Buy
- VTYX Buy
- Analyst Count
- BARK 3
- VTYX 3
- Target Price
- BARK $2.50
- VTYX $10.00
- AVG Volume (30 Days)
- BARK 793.3K
- VTYX 1.4M
- Earning Date
- BARK 11-06-2025
- VTYX 11-06-2025
- Dividend Yield
- BARK N/A
- VTYX N/A
- EPS Growth
- BARK N/A
- VTYX N/A
- EPS
- BARK N/A
- VTYX N/A
- Revenue
- BARK $470,831,000.00
- VTYX N/A
- Revenue This Year
- BARK N/A
- VTYX N/A
- Revenue Next Year
- BARK $6.25
- VTYX N/A
- P/E Ratio
- BARK N/A
- VTYX N/A
- Revenue Growth
- BARK N/A
- VTYX N/A
- 52 Week Low
- BARK $0.77
- VTYX $0.78
- 52 Week High
- BARK $2.56
- VTYX $4.03
- Technical
- Relative Strength Index (RSI)
- BARK 37.22
- VTYX 77.16
- Support Level
- BARK $0.80
- VTYX $2.64
- Resistance Level
- BARK $0.85
- VTYX $3.92
- Average True Range (ATR)
- BARK 0.03
- VTYX 0.31
- MACD
- BARK -0.01
- VTYX 0.14
- Stochastic Oscillator
- BARK 0.11
- VTYX 97.68
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.